All In Biotech

Drug Trial Radar · NCT06087094

A Trial of HRS-7450 in Chinese Healthy Volunteers

Randomized, Double-blind, Placebo-controlled, Single-dose Ascending Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7450 in Healthy Subjects.

Last checked: Nov 20, 2026Latest source record: Oct 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

50

Planned (sponsor's estimate)

Start

Oct 2023

Primary completion

Dec 2023

Study completion Dec 2023

Sponsor

Sponsor type
Industry
First posted
Oct 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this First-in-Human study is to evaluate the safety and tolerability after single ascending doses of HRS-7450 given to healthy subjects, compared to placebo..

Conditions

  • Cerebral Stroke

Interventions

  • HRS-7450 ;PlaceboDrug

    HRS-7450 or Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events (AEs)Time frame: 8 +/- 1 days
  2. Physical examinationTime frame: 2 days
  3. Vital signsTime frame: 2 days
  4. 12-lead electrocardiogram (ECG)Time frame: 24 hours

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.